Indeed, GDNF has been used in clinical trials, with variable success, showing improvement in PD symptoms in some cases [6], [7], but limited efficacy in others [8]; possibly because the GDNF was not reaching the target neurons in the substantia nigra and putamen [8]. This evidence concerns the gene GDNF and Parkinson disease.